Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular analysis of a CD19-negative diffuse large B-cell lymphoma.
Delage L, Manzoni D, Quinquenet C, Fontaine J, Maarek A, Chabane K, Mosnier I, Hayette S, Callet-Bauchu E, Grange B, Plesa A, Sujobert P. Delage L, et al. Among authors: hayette s. Haematologica. 2019 Mar;104(3):e114-e116. doi: 10.3324/haematol.2018.203521. Epub 2018 Dec 13. Haematologica. 2019. PMID: 30545922 Free PMC article. No abstract available.
BCR-ABL mutant kinetics in CML patients treated with dasatinib.
Nicolini FE, Chabane K, Tigaud I, Michallet M, Magaud JP, Hayette S. Nicolini FE, et al. Among authors: hayette s. Leuk Res. 2007 Jun;31(6):865-8. doi: 10.1016/j.leukres.2006.12.003. Epub 2007 Jan 8. Leuk Res. 2007. PMID: 17208297 Clinical Trial.
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
Nicolini FE, Hayette S, Legros L, Rousselot P, Maloisel F, Tulliez M, Guerci A, Charbonnier A, Prébet T, Rigal-Huguet F, Chabane K, Magaud JP, Paillet C, Pivot C, Michallet M. Nicolini FE, et al. Among authors: hayette s. Leuk Res. 2011 Jan;35(1):80-6. doi: 10.1016/j.leukres.2010.04.010. Epub 2010 Jun 3. Leuk Res. 2011. PMID: 20605207 Clinical Trial.
The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.
Nicolini FE, Chomel JC, Roy L, Legros L, Chabane K, Ducastelle S, Nicolas-Virelizier E, Michallet M, Tigaud I, Magaud JP, Turhan A, Guilhot F, Hayette S. Nicolini FE, et al. Among authors: hayette s. Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):394-9. doi: 10.3816/CLML.2010.n.073. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21030353
In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia.
Baseggio L, Geay MO, Gazzo S, Berger F, Traverse-Glehen A, Ffrench M, Hayette S, Callet-Bauchu E, Verney A, Morel D, Jallades L, Magaud JP, Salles G, Felman P. Baseggio L, et al. Among authors: hayette s. Br J Haematol. 2012 Aug;158(4):489-98. doi: 10.1111/j.1365-2141.2012.09178.x. Epub 2012 Jun 12. Br J Haematol. 2012. PMID: 22686190 Free article.
117 results